Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
February 9, 2023
Earnings Call Speaker Segments
James Bushnell
executiveGood day, and thanks for being here. We put out a press release earlier today with full details about how we did in the fourth quarter and across all of 2022. That release is available at pmi.com. You'll find a glossary of terms — covering what we mean by smoke-free products, along with adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures — plus extra smoke-free volume and net revenue data at the back of today's webcast slides, which are up on our site. When we present growth rates on an organic basis, those reflect currency-neutral adjusted results and leave out acquisitions and disposals. That means figures and comparisons shown on an organic basis don't include Swedish Match until November 11, 2023. As we've said before, beginning in the second quarter of 2022, and applied comparatively, PMI no longer counts amortization and impairments of acquired intangibles in its adjusted results. Remarks today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. With me today are Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer. Jacek, over to you.
Jacek Olczak
executiveAppreciate that, James, and hello everybody. In 2022 we enjoyed an outstanding year for our smoke-free transformations. Even with the extraordinary difficulties caused by the conflict in Ukraine, serious interruptions to supply chains and inflation across the globe, we achieved very strong financial results and made 2 significant strategic advances on the road to a smoke-free future. My heartfelt gratitude goes out to every one of my colleagues who gave everything to produce excellent business outcomes throughout these unprecedented times. Our thoughts remain as well with all those impacted by the conflict in Ukraine and the recent tragedy in Turkey and Syria. During 2022, PMI recorded a second straight year of growth in total volume, which mirrors ongoing progress for IQOS and largely steady cigarette volumes. Smoke-free net revenues for the full year came to nearly 1/3 of total PMI and above 50% across 70 markets. That marks impressive movement toward our goal of turning into a predominantly smoke-free company by net revenues in 2025. IQOS kept delivering outstanding results, with growth exceeding 21% for the full year in both shipment volumes and in-market sales, leaving out Russia and Ukraine. This mirrors wide-ranging momentum across the European Union region, Japan and emerging markets. IQOS ILUMA keeps producing excellent growth in its launch to market, with upgrades from current users and acquisition of new users beating our original expectations. This success is underpinned by growing deployment of a 2-tier heated tobacco units portfolio, which gives adult smokers a widening range of innovative and highly — and high-quality alternatives to cigarettes. Within combustibles, we turned in a robust performance, with organic net revenues up 3.7% and share of segment higher by 0.3 percentage points, leaving out Russia and Ukraine, even with the effect of adult smokers switching to smoke-free products. We reached 2 critical strategic milestones this year as well, securing an agreement to take full control of IQOS in the U.S. in 2024 and successfully finishing the acquisition of Swedish Match. These accomplishments will speed up our smoke-free journey and better position us to lead the transformation of the wider industry. Obviously, currency headwinds proved extremely strong and dragged on our U.S. dollar performance, yet while volatility persists, I am pleased they appear to significantly abate in 2023. All in all, 2022 proved a pivotal year, and we look ahead with confidence to 2023 and beyond. Allow me now to take a moment to address our key strategic priorities for the coming year. With the Swedish Match acquisition and the securing of the rights to IQOS in the U.S., we have become a global smoke-free champion. Adding the world's biggest market and the leading nicotine pouch brands ZYN, together with IQOS, hands us significant untapped opportunities to further speed up the growth of smoke-free products. As the strength of our IQOS business keeps growing rapidly, the full global rollout of IQOS ILUMA stands as a major priority, and we expect to make substantial progress on this in 2023. What ILUMA has achieved in its initial markets to date shows just how much a truly innovative, consumer-first approach matters, and we're expanding what we offer with additional science-based products. That includes BONDS by IQOS, the newest heat-not-burn option we've created for adult smokers with lower and middle incomes. Early results from pilot launches in Colombia and the Philippines during last year's fourth quarter look promising, and our plan is to absorb what those markets teach us prior to rolling out more broadly. After 3 successful years working with KT&G, we recently lengthened our long-term arrangement to bring their creative smoke-free lineup to markets beyond South Korea. It's a pleasure to have Swedish Match join the PMI family. ZYN's rapid growth potential, in particular, is a tremendously exciting thing for our company to add. Our attention is on helping the Swedish Match team sustain and speed up ZYN's remarkable U.S. performance, and on using PMI's commercial strengths to get nicotine pouches ready for expansion internationally. IQOS and ZYN are premium labels that head their respective global categories. Within the U.S., ZYN is assisting American smokers in moving away from cigarettes and holds strong growth prospects; as for IQOS, the largest smoke-free market worldwide remains completely untapped, and our preparations are advancing well ahead of commercialization in 2024's second quarter. To achieve a smooth roll-out, we'll draw on Swedish Match's sales and distribution strengths and put our commercial model, digital engine, organization and infrastructure to work. Our expectation remains that we'll submit an FDA application for ILUMA during 2023's second half. Naturally, growing pouches internationally, deepening IQOS penetration in the U.S. and swapping ILUMA in for IQOS 3 will mean extra investments this year, which together with inflationary pressure will temporarily drag on our margins. In fact, as Emmanuel will soon explain, a lot of the costs tied to ILUMA are one-off by nature; within combustibles, we keep aiming for a steady category share across time even with IQOS cannibalization affecting things, while making sensible pricing moves. As previously discussed, holding onto our combustibles leadership lets us push the most switching toward smoke-free products by way of our ties to adult smokers and the retail trade; on the financial side, our business's strength delivers solid operating cash flow, which we plan to maximize in order to fund reinvestment in smoke-free operations, deleveraging and a growing dividend. Lastly, and this matters greatly, advancing tobacco harm reduction by giving smokers better options and pushing for regulation grounded in science is essential to speeding up the end of smoking. Harm reduction sits at the heart of our transformation too, as we take the lead on sustainability to create positive impact; we'll cover more of this at the CAGNY conference on February 22, and we intend to hold an Investor Day this September, where we'll share much more on our strategies and future vision, especially concerning the U.S. At this point, I'll pass things along to Emmanuel, who will walk us through how 2023 turned out and what we're expecting going forward, with more specifics.
Emmanuel Babeau
executiveThanks, Jacek. Thanks to the power of our creative and growing smoke-free lineup, our company achieved outstanding 2022 growth on both the top and bottom lines, even though the operating climate was extremely tough and we faced currency headwinds. For the full year, our net revenues rose organically by 7.7%, leaving out Russia and Ukraine, and for total PMI they increased by 7.1%, even with the effects of hyperinflationary accounting in Turkey. That shows how IQOS keeps performing strongly, how pricing is picking up speed, and how combustibles have been recovering in many markets compared with a pandemic-hit baseline, particularly in H1. On the call, we noted that IQOS products accounted for about 5% of smoke-free net revenues for the entire year, whether or not Russia and Ukraine are included. On a per-unit basis, net revenue increased 4.4% organically when Russia and Ukraine are excluded, and 5.5% on a total basis. What drove that? Combustible pricing contributed a 4% gain excluding Russia and Ukraine, or 5% overall, along with a positive mix benefit as heated tobacco units, or HTUs, became a larger portion of our overall shipment volume—these units generate more net revenue per unit. Turning to 2022, our operating income margin contracted 60 basis points organically excluding Russia and Ukraine, and 70 basis points in total, reflecting multiple headwinds I plan to discuss later. IQOS expansion, price increases, and ongoing cost reductions helped counterbalance some of those challenges. Across 2022, we delivered $800 million in gross savings, which pushed the first two years of our cost efficiency initiative past $1.6 billion. Because of that, we're in a solid position to exceed the $2 billion goal covering 2021 and 2023, and to relieve some of the inflation we've been facing lately. Despite pressure on margins, robust growth in our top line combined with disciplined expense management allowed us to generate currency-neutral adjusted diluted EPS growth of 11.9%, reaching $5.34, with Russia and Ukraine excluded. Within that amount, you'll see an unfavorable currency impact of $0.85, along with a small boost from Swedish Match once financing costs are accounted for across the 50 days of consolidated results. For PMI overall, adjusted diluted EPS came in at $5.98, and we closed out the year on a strong note. Q4 organic net revenue grew an excellent 7.9% when Russia and Ukraine are excluded, which again shows IQOS continuing to perform well and combustible pricing holding up solidly. Our Q4 operating income margin rose 80 basis points organically, again excluding Russia and Ukraine, mainly thanks to an easier comparison. Looking at PMI as a whole, organic margins stayed flat, which reflects a tough comparison in Ukraine as well as the timing of shipments in Russia. Looking at Q4, adjusted diluted EPS on a currency-neutral basis rose 20.8%, reaching $1.23 when you set aside Russia and Ukraine. Including those two countries, the figure was up 15.3% overall, hitting $1.39 — a terrific outcome. Ahead of discussing what we expect for 2023, let me share where things stand with our operations in Ukraine and Russia. Our people in Ukraine continue to receive our support. I'd like to express my personal gratitude to them for the tremendous work they've done to keep the business running through these incredibly hard circumstances. When it comes to Russia, the path toward divestment has become increasingly difficult and tangled, particularly following the regulatory changes that took place in December 2022. So that investors can better understand the full scope of our operations, we are now incorporating both Ukraine and Russia into our 2023 guidance and reporting. Turning to what we expect in 2023, we're looking at really robust organic net revenue expansion, somewhere between plus 7% and plus 8.5%. The drivers behind that are a step-up in combustible pricing along with another year of swift gains from IQOS. If we hit that, it would be the third year in a row where organic top line growth came in above plus 7%, and keep in mind this excludes Swedish Match for the vast majority of the year. Once you factor Swedish Match in, our reported currency-neutral net revenues should climb into the teens, since that business kept up its strong performance. We also expect outstanding IQOS momentum to lift our HTU volume growth on a total PMI basis, helped by ILUMA's expanding presence in our key markets. Our projection for HTU shipment volumes falls in the range of 125 billion to 130 billion, which works out to growth of 15% to 19%. That marks a faster pace than the overall PMI growth rate posted in 2022, even though we don't anticipate meaningful movement in Russia, since we've chosen to limit both investment and innovation there. As we've noted before, the rollout schedule for ILUMA has likewise been held back by disruptions in the supply chain along with the stronger-than-expected uptake seen in the first launch markets. Through the first half, we look for those constraints to ease step by step as we bring the product to additional geographies. For this year, we anticipate that organic smoke-free net revenue growth will track in line with the rate of HTU volume growth, with fewer distortions coming from device revenues. If we include Swedish Match and hold exchange rates steady, our smoke-free net revenues should come in at roughly $13.5 billion, up from $10 billion in 2022, and account for close to 40% of PMI's total net revenues this year. Our top line outlook is very strong, but the reality is that, in common with plenty of other multinational businesses, we're dealing with considerable margin pressure caused by inflation that keeps intensifying, along with several particular one-off factors and investments that I'll address in a moment. Consequently, on an organic basis, we anticipate our adjusted operating income margin will narrow by 50 to 150 basis points. On that basis, our projection for currency-neutral adjusted diluted EPS growth is plus 7% to plus 9%. On this, you're getting a whole year of favorable impact from Swedish Match, with the associated interest expense taken into account. But that gain gets canceled out by higher interest costs tied to our debt outside of Swedish Match, along with planned investments. The result is an adjusted diluted EPS range of $6.25 to $6.37, and that figure includes $0.15 of unfavorable currency at prevailing rates. One thing worth noting: this forecast doesn't build in any possible favorable court decision in Germany about whether the surcharge on the existing excise tax for heated tobacco products, effective in Germany as of 2022, is legal. In our results and outlook, we keep accounting for the excise surcharge. That said, the requirement to pay it is presently on hold. If we get a positive outcome there, then the change to the excise payment we expect for 2023 would increase net revenue by around 1% and add roughly 3 points to adjusted diluted EPS growth, pushing our currency-neutral growth projection to somewhere between plus 10% and plus 12%. In that case, we would expect operating cash flow to land in the upper half of the range we've forecast, and we think a decision will come late in the year. Several other assumptions also underlie our outlook. In markets outside China and the U.S., we expect combined international industry volume for cigarettes and heated tobacco units to decline by minus 1% to minus 2%. Given how far ahead we are in smoke-free products and how quickly that segment is growing, we anticipate gaining share, and our goal for total PMI shipment volume is somewhere between unchanged and a 1% increase — that would be our third consecutive year of growth. While we intend to keep our portion of the combustible category steady, given the inflation we're seeing now, we're assuming combustible pricing will accelerate to about plus 6% on an organic basis, compared with the plus 5% we achieved in 2022. We also expect capital expenditure for the full year to come in around $1.3 billion, which is higher than the $1.1 billion recorded in 2022, as we put more money behind our smoke-free platform, ILUMA and the Swedish Match portfolio among them. Let me now go back to the different elements that play into our margins.
Emmanuel Babeau
executiveDuring 2022, our total PMI gross margin shrank organically by 220 basis points. Rising inflationary pressure certainly hurt, but the biggest factor was the mix of ILUMA's swift expansion plus one-off items like supply chain interruptions and having to rely on air freight. ILUMA prompted faster device upgrades among current users in Japan and other early launch markets. Those device sales help acquisition, retention and full conversion; still, devices dilute margin, and that pattern will probably persist for a while as we bring the product to additional markets this year and consumers move up from the IQOS blade. The initially heavier weight and higher cost of the ILUMA consumable mattered too, which meant the heat-not-burn business overall, devices included, diluted margin in 2022. Crucially, average gross margin for HTUs stays roughly 10 percentage points above cigarettes, on greater net revenue per unit; that's a basic long-term favorable margin driver as HTU volume mix expands within our business. It delivered a favorable impact of plus 110 basis points in 2022. Pricing and productivity, our 2 other main long-term margin drivers, kept contributing positively as well. At the operating income margin level, SG&A costs offset gross margin headwinds, falling by 150 basis points of net revenues mainly because of cost efficiencies, operating leverage and a comparison effect. The 2023 picture looks rather different, even though our gross margin will confront greater inflationary pressure. That pressure now stems chiefly from COGS in the cigarette business as leaf, asset tow, salaries and energy costs rise. Faster combustible pricing and reduced air freight expenses will help offset this unusual inflation. Still, our projections incorporate a time lag. Crucially, although cost inflation is a headwind for IQOS too, the 2023 margin effect of our heat-not-burn business should be favorable, thanks to the positive effect of higher HTU volume at greater net revenue per unit, planned ILUMA efficiency and a more moderate rise in device volumes. On the whole, this underlying strength from IQOS along with pricing won't be enough to counter combustible cost inflation in 2023. Even so, we anticipate a smaller organic gross margin decline than last year. And we expect our heat-not-burn business to show an increasingly visible positive effect as 2024 gets closer. 2023 SG&A costs will contain added investment to fuel future growth, among it the commercialization of ILUMA. Also in there is roughly $150 million, split broadly evenly between the U.S., where we are building our organization's capability ahead of the IQOS launch, and wellness and healthcare investment in product development and clinical trials. Beyond inflation, that points to an SG&A cost increase more aligned with net revenue growth, with limited margin effect. A few words now on 2023 phasing. We anticipate that margin pressure will be concentrated in the first half, especially because of the tough comparison against Q1 2022 and a steady decline in air freight expenses over the course of the year. On top of that, investments should be weighted toward the front end, and we recognize that the ILUMA rollout may bring about a brief stretch of slower user acquisition while consumers hold off for the launch. Together with the timing of shipments and cost savings, we anticipate that our 2023 top and bottom line performance will be heavily weighted toward H2. In fact, we see the first quarter as the toughest, with organic top line growth in the low single digits and weak margin. The effects of shipment timing and the ILUMA launch should be significant, and as a result we expect HTU shipment volume of roughly 26 billion to 28 billion HTUs. We also confront a comparison in which the impact from war related disruption is considerably smaller; we project adjusted diluted EPS of $1.28 to $1.33, which includes $0.10 of unfavorable currency at prevailing rates. Crucially, we anticipate margin improvement as we move toward 2024, as headwinds ease and the fundamentally margin accretive driver of our smoke-free transformation persists through heated-tobacco unit growth, pricing and cost optimization on ILUMA. Our cash flow generation continues to be robust; we generated $10.8 billion in 2022 operating cash flows, which represents plus 3% growth on a currency-neutral basis. That figure includes the favorable timing of certain financing items of approximately $0.3 billion. Because nonrecurring items and working capital movement benefited 2021 by roughly $1 billion, this was a superb outcome. For 2023, we project $10 billion to $11 billion in operating cash flow even though we expect a notable impact from higher working capital requirements driven by growth, global inflation and the reversal of one-off timing benefits. This keeps us on track to meet our '21/'23 targets of approximately $35 billion set in February 2021 at then prevailing rates. Although our net debt stands at 2.9x adjusted EBITDA on a 12-month trailing basis, that reflects only 50 days of Swedish Match results; including a full year contribution for Swedish Match would plainly produce a lower ratio; we aim for robust EBITDA growth, which together with strong cash flow lets us concentrate on deleveraging while still investing in innovation and the growth of our business. Furthermore, our dedication to our progressive dividend policy is steadfast and consistent with our long-term commitment to returning cash to shareholders. Returning to our 2022 results. Both our HTU and in-market sales volume rose by approximately 21.5%, underpinning total volume growth of plus 3.2%, excluding Russia and Ukraine. Q4 HTU shipment volume increased by plus 37.5%, partly reflecting inventory replenishment for ILUMA in Japan after lower shipments earlier in the year and favorable shipment timing in the EU, particularly ahead of new ILUMA launches. Backed by very solid cigarette performance, we achieved total volume growth for the second year in a row, both including and excluding Russia and Ukraine. Now turning to combustibles. For the entire year, our portfolio achieved strong organic net revenue growth of 3.7%, leaving out Russia and Ukraine. During the second half, combustible pricing went up as we kept adapting to the inflationary climate. That produced organic pricing in Q4 of 4.8%, again excluding Russia and Ukraine, and gave us full-year pricing that matched what we had anticipated, with significant input from Germany, the Philippines and Turkey, even with hyperinflationary accounting affecting results. Across 2022, our cigarette category share rose 0.3 percentage points, excluding Russia and Ukraine, after category share losses in 2020 and 2021 that the pandemic made worse; this covers quarter-by-quarter gains throughout all of 2022. Marlboro is still highly resilient even with disposable income under pressure and IQOS cannibalization weighing on it, posting segment share growth of 0.2 percentage points; also, though no meaningful acceleration in down trading has appeared yet, our share within the low-price segment climbed 0.6 percentage points, excluding Russia and Ukraine. As Jacek said before, holding onto our cigarette category leadership is a crucial enabler for speeding up the shift of smokers toward better alternatives. A solid cigarette share paired with IQOS expansion gave us an overall market share improvement of 0.6 points in 2022, excluding Russia and Ukraine, with major contributions from Egypt, Italy, Japan and Poland.
Emmanuel Babeau
executiveIn markets where IQOS is available, PMI's heated tobacco unit kept reinforcing its path toward becoming the biggest nicotine brand, and in 2022 it secured the #2 spot, hitting a record share of 8.5% during Q4. Let's turn now to how the IQOS user base is expanding. As of December 31, we counted an estimated 20.3 million IQOS users, leaving out Russia and Ukraine; that marks an increase of roughly 3.5 million across the entire year; when we look at PMI as a whole, we figure there were nearly 25 million IQOS users at year end. During October and November, as we mentioned in a recent disclosure, user growth decelerated. Reduced commercial activity had a larger impact than we had expected, and acquisitions for the IQOS blade product were weaker before ILUMA's introduction in a number of key markets. Even so, December delivered a strong bounce back, with ILUMA rollouts continuing, which generated healthy user growth of $0.8 million more for the quarter. That result came fairly close to our original expectations, and we enter 2023 with confidence as ILUMA continues to be deployed. In every market where it is available, ILUMA is driving volume and share improvements, and this supports our strong position in heat-not-burn. We entered 8 additional markets during Q4, among them the Czech Republic, Italy, Portugal and South Korea, which lifted the total to 16 markets, and ILUMA launches now account for over half of our overall HTU volumes. ILUMA provides a better consumer experience, as shown by Net Promoter Scores, which rose on average by over 10 points across its various market architects, along with a higher conversion rate relative to IQOS 3 DUO. although the pace of acceleration varies from market to market, in Switzerland and in the more recently entered United Arab Emirates, offtake share has nearly doubled since launch. As I mentioned earlier, it's important to note that because of the benefits that come from scale and optimization, we should be able to bring down ILUMA's cost over time, starting in the latter part of 2023. Now looking at the European Union, smoke-free net revenue there accounted for over 40% of the region across the entire year. In Q4, our HTU share went up by 2.4 points, hitting 8.8% of combined cigarette and HTU industry volume, helped slightly by some favorable timing effects. On a four-quarter moving average basis, IMS volume continued to climb each quarter and reached an all-time peak of 9.3 billion units. That reflects wins across numerous markets and major cities, including Vilnius, where share tops 43%, along with Athens and Rome, each above 25%. Turning to Japan, heat-not-burn accounts for nearly 35% of the total tobacco category now, and IQOS is driving more and more of that expansion. During Q4, adjusted total tobacco share for our HTU brands climbed 2.6 points to 24.5%, while offtake share in Tokyo came in above 30%. Strong performance continued from our 2-tier consumable portfolio. On IMS once more, sequential growth took it to an all-time peak of 8.8 billion units measured on the 4-quarter moving average, while the count of adult Japanese IQOS users passed an impressive 7.5 million; beyond solid IQOS momentum in developed markets, we're still seeing highly encouraging expansion across low and middle-income markets; during 2022, our HTU shipments were up by nearly 50%, leaving out Russia and Ukraine. That strong showing mirrors wins in numerous markets, among them Egypt, where Urban Cairo's exit offtake share went beyond 7%, plus Bulgaria and Malaysia, where Q4 offtake share hit 14% in each capital city. Now let's discuss Swedish Match, which closed out the year performing well and strengthened our belief that this combination will enhance both our growth and our margins going forward. A quick administrative note: any details I share regarding Swedish Match's financial performance come from information that is publicly available up to September 30, as well as from November 11 onward, when the company became part of PMI's consolidated financial statements. Once the acquisition was complete, Swedish Match delivered outstanding results, with robust net revenue and adjusted operating income. The most impressive highlight was ZYN's extraordinary expansion in the United States, a topic I'll cover further on the following slide. Regarding other U.S. On the smoke-free side, moist snuff turned in a solid performance as well. It gained close to one percentage point of segment share and grew its volume in 2022 even though the category itself was contracting. Over in Scandinavia, both the total smoke-free market and Swedish Match continued to expand, although that growth was helped in part by trade inventory movements at year-end, ahead of a general excise tax hike in Sweden. The cigar business delivered a robust showing to wrap up a difficult year, with increases in both volume and category share. We're extremely pleased with how strongly Swedish Match performed in 2022, which also included favorable pricing in every smoke-free category. Going forward, we look forward to sharing our combined results. Let's now take a closer look at how ZYN has been performing recently in the U.S. We keep moving forward at a strong pace, with shipment volumes up 37% across 2022 and 35% during Q4, which marked a record high for any quarter. Compared with Q3, ZYN's share of category volume climbed 1 percentage point, and it was 2.2 percentage points higher than a year earlier. That makes its standing as the obvious top nicotine pouch brand even firmer, even as competitors with cheaper products keep discounting aggressively. On a retail value basis, ZYN's share stayed solid at 75.7%, which speaks to its premium position and the strength of the brand's equity. The year ahead, 2023, looks set to be extremely exciting. We're really happy to have Swedish Match's team and their top-notch nicotine products now part of the PMI group, making us a worldwide leader in smoke-free options. Together, we'll generate value as we speed up progress toward the smoke-free future we both aim for. Specifically, combining ZYN with IQOS across the U.S. and other global regions gives us a big chance to boost growth and help more adult smokers move to better choices. Since Swedish Match is a successful, well-operated company, we anticipate its current operations will keep performing strongly. A key focus for us this year is supporting ZYN in the U.S. and accelerating its positive trend even more. Beyond that, we're getting ready right now to take nicotine pouches into markets worldwide, drawing on the strong product lineup that came with Swedish Match as well as the broad smoke-free commercial setup PMI already has. At the same time, we'll be working hard to upgrade Swedish Match's distribution and commercial strengths inside the U.S. ahead of the IQOS rollout in 2024. Let me turn to sustainability. While we reshape this company, both our business plans and our sustainability plans keep moving forward, and they're picking up speed as we go. PMI and Swedish Match share the same vision and ads. Pulling these efforts into one place accelerates our progress on the mission — changing things for the better so that cigarettes are phased out and the benefits of smoke-free products reach their fullest. Striving for top-tier ESG results fits right in with how we're working to address the environmental side of what we produce, end child labor, reduce the carbon we emit, and build a workplace where all of our people feel included and empowered. Last December, we released a separate report that set out our new goals regarding biodiversity and water. When it comes to biodiversity, we aim for no net loss throughout the ecosystems connected to our value chain by 2033, along with helping move nature toward a net positive impact by 2050. When it comes to water stewardship, we've set a goal of expanding solutions that deliver a beneficial effect on water resources by 2033, and by 2050, we aim to contribute toward a beneficial effect on water resources.
Emmanuel Babeau
executiveOne more point I'm glad to mention: CDP has given us its 'Tripple A' designation for a third year in a row. Out of roughly 15,000 businesses that CDP evaluated on disclosures tied to climate change, forests, and water security, a mere 12 earned that distinguished rating. I'm also pleased to note that we appear in the 2023 Bloomberg Gender Equality Index, marking our third straight year on it. With that, I'll hand things over to Jacek, who will wrap us up.
Jacek Olczak
executiveThanks, Emmanuel. All in all, despite plenty of difficult headwinds, our company turned in a solid fourth quarter as well as a solid performance for the entire year. We posted outstanding growth on both the top and bottom lines, with adjusted diluted EPS climbing by double digits in currency-neutral terms and total PMI adjusted EPS coming in at nearly $6. Over the past 3 years, the steady quality and durability of what we deliver organically on the top and bottom lines has been made very clear. What stood out most was IQOS continuing its superb performance, which ZYN's extraordinary expansion now supplements. Together with Swedish Match, we hold a full global smoke-free portfolio, with leading positions in heat-not-burn and in the fastest-growing segment of overall nicotine. For our smoke-free transformation, we anticipate 2023 will be a landmark year, with smoke-free net revenues at constant currency of roughly $13.5 billion, nearing 40% of our company. We see thrilling chances to expand nicotine pouches both in the U.S. and around the world, plus the U.S. commercialization of IQOS next year. We anticipate margin headwinds will last through 2023 before getting better in 2024. Even so, our underlying growth fundamentals stay solid, and we look forward with — and we look forward with confidence. Given a superb performance across the past 2 years and our robust 2023 outlook, we anticipate comfortably beating our 3-year minimum CAGR targets: more than 5% organic net revenue growth, more than 9% growth in currency-neutral adjusted diluted EPS and broadly stable shipment volumes. Lastly, our robust growth outlook and highly cash generative business let us deleverage while keeping our unwavering commitment to our progressive dividend policy. Thanks for listening. Emmanuel and I are now glad to take your questions.
Chris Growe
analystLet me begin by saying the color and detail you provided in your comments were excellent. When I examine the EPS growth for 2023, I just want to grasp what burdens are weighing on it. We're aware of roughly $150 million in investment that you've laid out for the U.S. along with your Health and Wellness division. What additional costs do you anticipate around supply chain expenses and the use of air freight, for instance — how much are those weighing on your costs for the year? Could you offer some insight there?
Jacek Olczak
executiveSure. Perhaps I'll kick things off, and then Emmanuel will jump in, I suppose. Right, it's $150 million split between the U.S. — $150 million split between the U.S. and the Wellness and Healthcare, divided almost equally between the 2. Then there's their freight, and this is more the issue, which I believe we ought to begin witnessing some improvements on in 2023, and particularly as we move toward the second half of the year, I think we ought to begin normalizing the use of their freight, which will then clearly carry on into the 2024. Then there's the inflationary pressure on the COGS. I think Emmanuel brought up in his comments that the leaf clearly is the thing that — because of how long we hold inventories of the leaf and the manner in which the leaf prices flow through the P&L, something that typically persists longer, you have a concern regarding how long inventory is held; so on a moving average, valuation I mean, it gets spread across the period of time. Then there's energy, which is clearly the major blow across a number of — directly or indirectly for the materials. Now we're beginning to see energy prices letting up at least at this point, but you're also constrained by certain contractual arrangements, and so on; so I don't believe this is assisting at '23, but I stay cautiously optimistic as of '24, we ought to begin seeing a reversal of those. Clearly, there's the cost of the IQOS ILUMA roll-out, correct? Since we are — by the year-end, we've been at the 16 markets out of 73 markets, total IQOS; so there's a substantial portion of the market ahead of us in '23, and we don't wish to halt or decelerate the runout of ILUMA; so clearly, there's pressure on the margin stemming from the additional sales of the devices, right, which clearly are the drag on the margins, and we've essentially been speeding up replacement of the devices at the level of existing consumers but with a very clear view now that we have a very nice paper going forward with the accelerated acquisition, better consumption or better conversion rates. And those are the key items. Emmanuel, if I've missed something important?
Emmanuel Babeau
executiveNo, I believe you've covered things quite thoroughly, that's clear, yes — only a few more specifics. Of course, during '23, we've been calling this out. Our heat-not-burn segment should make a favorable contribution when it comes to how the gross margin rate moves. So really, in '23, it's inflation hurting us badly across every cost of goods line. On convertible, we will raise price, yet that won't be enough to counterbalance the effect. And just to give you a sense, Jacek mentioned energy prices. We aren't even discussing inflation in the double digits here. I mean, for energy prices comparing '23 with '21, we're talking roughly a 3x multiple. So that's a substantial rise with a substantial effect on the P&L across time; through price increases, we'll get past it, but as we said, there's simply a delay in catching up. Then there's also a major distinction regarding how our SG&A cost develops. During 2022, we held flat since we'd been producing many efficiencies. Inflation wasn't as severe as it will be in '23, with plenty of salary increases, and likely the comparison base was more favorable. In '23, we anticipate growing our SG&A roughly in step with top line, which is more or less what you'd expect; we keep investing heavily to back the business's growth, to bring in new users, digital investment. We refer to the U.S. and Wellness and Healthcare. And efficiency will remain, though not to the same degree. The final item I need to mention is the cost of the debt. I'm not referring to the debt from acquiring Swedish Match, because regarding Swedish Match — we're meeting expectations, that is, low single-digit accretion on the EPS. But clearly, for the debt already in place, the cost has risen too, and that is affecting how adjusted EPS evolves. With that, Chris, I think we're providing everything we can regarding what we face in terms of cost evolution.
Chris Growe
analystThat was certainly thorough, and it helped a lot. I only have a single brief follow-up, and it concerns the heat tobacco unit growth figure you gave, the 15% to 19%. I'd simply like to understand two things about it. Is Russia and Ukraine likely to be down in 2023, since you aren't putting money into those markets? And second, how much is capacity the constraint right now — if you had additional ILUMA capacity, might that expand at an even quicker pace?
Jacek Olczak
executiveAlright. Well, in fact, Russia and Ukraine, and clearly Russia because of its scale even more so, acted as a drag on how we performed in '22, and it's reasonable to expect the same drag in 2023. As you're aware, it's our choices, our firm choices not to put money in, and basically ILUMA, for instance, being the crucial technological step forward, which we chose against launching in Russia, that has a consequence, correct? So the figures we're giving now, purely for the sake of showing investors the business as it stands today, do include Russia and Ukraine, yet neither — and very much not Russia — adds anything to growth; so one positive is that if you left out Russia and Ukraine, our growth rates would sit at a higher level on a like-for-like basis. On capacity, we will — I believe we have — we're telling the market that we'll — we anticipate improved results during the second half of the year, and that partly mirrors the point at which we believe we'll be past the bottleneck regarding ILUMA capacity. So we're already running the business with an extremely tight supply chain all through this year — pardon me, 2022 — and into the first half of '23. And in the second half of '23, we ought to be — we ought to be fine. That again — I can connect it back to the well-known air freight and so on, since every one of those things stems from us operating on a very tight supply.
Bonnie Herzog
analystMy first question concerns the operating margin guidance you gave and the deleverage that's implied by it. Could you unpack a little more the headwinds you called out? And when we consider the things within your control, such as the spending you're doing to fuel growth down the road, can you frame that for us? I'm just attempting to work out how large an increase in investment this year will be relative to last year. After that, how should we view the spending needed in the following year and further out? What I'm trying to grasp is what portion of that investment is necessary basically to bring IQOS to the U.S. market. Will that happen during this year or the next one? I fully understand the spending required to introduce ILUMA, but any detail on that would be useful.
Emmanuel Babeau
executiveGlad to address that, Bonnie. In the U.S., we've made it clear that we anticipate roughly half of $150 million. Naturally, that's an approximation of the additional investment in the U.S. as we get ready to launch IQOS there; this applies to 2023. Once we have a plan covering the years ahead, and naturally with greater specificity, we will certainly reach out and lay out the details for you. As for the remaining parts of the business, I believe we are — and this was the point behind what I said about how SG&A is developing. Fairly routinely, we put in an additional few hundred million, and I'd ask you to let me keep it less precise, since that is, naturally, sensitive information, to support IQOS's acceleration, and it will, naturally, support IQOS ILUMA during 2023. Regarding growth, when we state that we anticipate SG&A rising roughly in step with the top line, inflation has an enormous effect. I don't think I need to spell out that inflation sits at around high single digits in most nations, and we must account for that in pay raises; we offset it through cost efficiencies, and that lets us, on top of the inflation effect, keep putting money into growing the business. This we do fairly consistently, naturally with a strong focus on supporting ILUMA during 2023.
Bonnie Herzog
analystAll right, that's useful. If I could, one more thing. It has to do with how the user base for IQOS grew during Q4. Would you be able to walk us through a few of the positives and negatives from that period? What I mean is, it looked like things sped up compared with Q3 even with certain challenges you'd pointed to not long ago. You also said ILUMA produces better conversion numbers compared with IQOS 3 DUO. So might you put a figure on that for us? What I'm getting at is, once that platform reaches scale, would you anticipate your total conversion rising substantially, perhaps beyond the 70% level you're at now?
Jacek Olczak
executiveSure; let me handle that one. At this point, ILUMA conversion figures across the markets < >, the run rate conversion figures prior to the IQOS blade would sit roughly around 10 percentage points, all right? Clearly, each market differs, and the fit varies somewhat from place to place, yet as a general guideline it's roughly those 10 percentage points, and what that basically tells you is that under the way we track conversion, 10% of devices sold via bringing in new users are in use, and they ought to — and indeed they do — create repeat demand for the consumables. So there's also — you get improved efficiency when it comes to acquiring users and the units sold. Let me connect this to what you asked earlier, Bonnie, if that's okay. Regarding the U.S. spending, we called out roughly $150 million, counting Wellness and Healthcare, yet we ought not to view that spending purely through an IQOS lens, since a portion of it — which we've already begun and which we pledged to carry out this year, as I see it — will additionally open up more growth potential for ZYN, all right, for Swedish Match; so it isn't as though we genuinely operate this as a pair of distinct businesses, because we aim to view it in terms of leveraging and further strengthening Swedish Match's capabilities, and I think the chances for ZYN in the U.S. — they enjoyed remarkable, extraordinary growth, depending on which target you prefer, yet I believe there's additional upside ahead here. So in how we approach deploying the resources, it won't merely get us ready for the IQOS stake returning in '24, but in the interim can further — can provide an added lift to ZYN; now, on your other point regarding the later launch of IQOS by itself in the U.S., I think in September, when we get together, hopefully at the Investors Day, we'll be able to offer more detailed plans. Naturally, we factor in the anticipated timelines with respect to the FDA. We indicated we'll be filing for IQOS ILUMA, which is our top flagship and the strongest offering available right now; and clearly, our aim — our chief aims would involve entering markets, the U.S. There's a lot of strong momentum in these markets, driven internationally by the best offerings we have; however, my expectation is that by September of this year, we'll gain additional specifics and clearer visibility regarding this matter.
Gaurav Jain
analystTwo points — first, about the higher cigarette pricing. A year ago, that figure stood at 5%. What you're signaling now is 6% for FY '23. In Japan, pricing came in at 5% a year ago; for this year, it's going to be zero. So it's clear that once you strip out Japan, cigarette pricing is speeding up from roughly 4% to 7%. So precisely where is that substantial step-up in cigarette pricing taking place?
Jacek Olczak
executiveJapan, quite solid, in this instance a single market outside Japan, correct? It's the largest in pricing coming from the unknown, right? When it comes to Japan, it's tough to make predictions. But this year we've already been doing quite well, thanks to solid outcomes from reversing the pricing trend in Indonesia — you might remember that. I'd say we truly turned a corner there, and that's largely because of the underlying volume size and how significant that business is for us. The Philippines is stronger in my view, since the European markets also bring strong pricing. So the 6% we're assuming for this year simply reflects that. From here, it hinges on what happens in Japan. All these factors, I mean, will pile on top. If we're talking about the major regions, though, Japan stands out as the one place where, for reasons everyone understands, we just can't see very far ahead.
Gaurav Jain
analystSure. Then regarding this EU ban on heated tobacco flavors, which is supposed to arrive later in the year, what should our thinking be? And in what way is it included in your guidance?
Jacek Olczak
executiveI'd say it's among those situations that no one has ever gone through. We can draw certain parallels to the flavor bans, menthol included, on the combustible side, as you might remember from a few years back, and honestly, it did not produce any meaningful effect on cigarette volume. So I believe here — all right. We'll observe what unfolds. Our view is that it will be something we can handle.
Pamela Kaufman
analystCould you talk about what you're planning for Swedish Match in the U.S. this year and what matters most to you there? Then, what's the approach for taking ZYN international, and when will that happen?
Jacek Olczak
executiveSure. Clearly, our aim is to keep up and build on the tremendous growth that pouches have been seeing in America. When I responded to a different question earlier, I noted that some of the money we're putting into the U.S. should, in my view, also help Swedish Match's existing operations. Better pricing ought to be there, particularly for cigars, and even though that isn't truly where our strategic attention lies, it still clearly lifts how the whole business does. Regarding our longer-term approach — the major issue, of course, is the way we'll handle IQOS going commercial once we completely bring it back during 2024. We understand which kinds of real capabilities Swedish Match is lacking. So those are being added by us; however the genuinely large commercial outlay will hinge on when and how aggressively we roll things out, and we'll probably reveal that near September, at the investor — around this September, at the Investors Day. As for pouches internationally, I'd say Swedish Match and ourselves, now combined, have a plan for beginning to deal with certain share pressure, particularly across the Nordics, all right? Yet at a wider global level, there are a fair number of countries where we'll begin introducing the pouches during this year, and for clear reasons I won't say which ones. Still, that was the entire rationale behind buying Swedish Match. As you remember, drawing on the growth opportunity base in America is an enormous comfort when it comes to being ready for IQOS. Beyond that, I think this category holds considerable promise within RRP — reduced-risk products — on an international footing. So infrastructure exists for us across the majority of markets, and it's — I'm not actually putting out — revealing anything strategically confidential. Naturally, IQOS can be found in more than 70 markets; that's where the developed infrastructure is furthest along, and in all likelihood the market for ZYN products is going to fall inside that list of markets.
Pamela Kaufman
analystCould you also discuss the plan for the bonds product introduced in test markets, plus what you've seen so far? And how are you viewing a wider launch down the road?
Jacek Olczak
executiveSure. I'd say the wider launch of the bonds, or the more strategically scheduled one, is set for 2024, meaning the following year; we'll see some volume, though frankly nothing near what we have with the IQOS and ILUMA product. That remains by far the main priority. Still, I'd say the initial results, which we'll receive from the Philippines and Colombia — they're quite strong. In fact, they're quite strong. Naturally, given roughly 7 years of experience with IQOS products, our expectations run far higher than they ever did. So bonds must arrive and satisfy those expectations too. As for the offering, we understood that as we move further into emerging markets, with lower income, where affordability for consumers could mean a bit of a delay in reaching our smoke-free goals. We also needed to develop a technology, for both the consumables and the device, that in some way aligns the cost of the offerings with the potential pricing we can — we can present to the market. So clearly, the emphasis will fall on emerging markets; yet I do think that this offering will also, helpfully, assist in certain developed economies, given the range of the smoker population. Of course, there's also the group whose financial means might pose some limitations. So it will be a really good complementary offering within our portfolio. And basically, it also supports IQOS in carrying on its remarkably successful record of holding this premium or medium plus position. This is the mega brand we're striving to build while getting ready for the fact that — you know, there are 1 billion-plus smokers globally. I mean, they span the various price tiers, from premium and mid to low, super low, and so on, and we must supply the appropriate offerings there; so I believe BONDS is on course, and that's how we'll act strategically within the portfolio.
Vivien Azer
analystCould we please discuss the IQOS outlook, specifically regarding the stakes? More specifically, how does removing characterizing flavors from HTUs in the EU affect your forecast? In what way are you factoring that in? And please, what is the anticipated timing for this?
Jacek Olczak
executiveYes. I gave a partial answer to that earlier, Vivien. But the character lies in flavor. We went through this before with cigarettes, combustible cigarettes; that's the sole benchmark available to us at present. As you remember, the menthol and other ban across Europe didn't materially affect cigarette volumes at all; so here, I'd say one could anticipate a comparable, manageable sort of effect, so to speak, from that < >. Another point deserves reminding everybody: IQOS today is unquestionably the top tobacco flavor offering. Yes, certain flavors exist in our market portfolio where proportions could vary. Yet unquestionably, IQOS excels at pure tobacco flavor, and incidentally, that's where most of the cigarette market sits, the remainder basically across all geographies. What I mean is, this is an IQOS strength; so one segment of the portfolio will take a hit. Still, I believe for most current smokers — pardon me, current IQOS-competitive users plus smokers who remain on combustible — I mean, IQOS continues to deliver today the finest taste and flavor experience, centered on tobacco flavor.
Vivien Azer
analystMy apologies in case I overlooked it, but could you possibly give us an update regarding how the infrastructure build-out for IQOS in the U.S. is going, prior to your reacquisition of the commercial rights proposition, covering both the consumables side and the devices side?
Jacek Olczak
executiveYeah, I think there was — see, there was — we are also examining this, and not just for IQOS on a standard basis, but for IQOS together with the ZYN and other segments of the Swedish Match business. I think the natural questions about what distribution is optimal, and I think this could very well be an enhancement — sorry — the distribution serves not only a future IQOS, but can and will actually serve ZYN growth opportunities today. There's the entire digital element. There's improved handling of pricing promotions, the entire consumer piece, correct? Which is so powerful behind an IQOS success. I mean, that's something for which we are getting the infrastructure ready.
Owen Bennett
analystYeah. What I want to ask about is really the larger picture and the longer horizon, specifically regarding the United States and the entire RRP category, since you now control your own fate. I'd love to hear how you expect RRP as a whole to evolve over a longer period across the various segments — do some of them strike you as more appealing than the rest? Also, do you remain of the view that heated products can become substantial once launched in America, keeping in mind the modest pickup Altria managed? And tied to those American RRP ambitions, is there anything new on when a PMTA filing for your vape product might happen?
Jacek Olczak
executiveYeah. Let me take the final item first: we intend to file the IQOS ILUMA with the FDA through the PMTA route during this year's second half. Turning to the potential — in our view, the IQOS proposition is truly, when you reach the heart of today's smokers who genuinely take pleasure in this pure product untouched by any flavors and so forth, the tobacco taste and similar is beyond question. In every single market, IQOS delivers precisely against what this group expects in terms of flavor and taste. That, I'd argue, is likewise a vital element behind the strong conversion rate IQOS achieves, and the number of individuals who embrace IQOS completely. And beyond that, they abandon cigarettes entirely, without even trying now and then to return to them, right? So that's the essence. And my view is that among the smoking population we have in America, IQOS slots in perfectly with all of this. Clearly, the remaining platforms give you a different ritual and a different experience — cigarettes and the pouches. Cigarettes tend to be pushed more by flavors, and clearly, with the pure natural tobacco-style taste missing, that's the difficulty, which in our view partly explains greater dual usage and less than full conversion — though those products are in development and improving. Pouches, meanwhile, sit on the risk continuum of the product. What I mean is it's yet another significant option for consumers who genuinely seek a major reduction in exposure and possibly in harm while still enjoying the product. So I'd say there's a complementary — each of these platforms plays a complementary part, and on top of that we're developing our own platform, internally, which is the leaf and Viva products; the electronic cigarette segment is moving through its own patterns, and this blend of flavors, disposables and so forth isn't exactly wonderful for the economics, but partly it's also due to that lower conversion rate relative to the other platforms. So we've stated this from the outset of our transformation — if you've tracked us 7, 8 years back, I remember one of the earliest investor conferences when we laid out the power plays, that we intend to go smoke-free. We've mentioned that each platform can find its place at various times for various consumers; and what we need to do is, at the appropriate moment, roll out these platforms and take advantage of the opportunities and the value for the smoker.
Owen Bennett
analystGreat, that's fantastic. And I apologize — a quick follow-up: my PMTA question wasn't about ILUMA. As I recall, previously < >, you mentioned aiming for the first half of '23. Any news at all on the PMTA submission?
Jacek Olczak
executiveYes. We're likewise looking at 2023, I'd say, but with ZYN now in the picture too, plus what we know ILUMA is capable of, and what we know about P4, we also have to be certain our PMTA submission strategy is the correct one, correct, since each of them demands effort, and prioritizing becomes necessary; though I'd put it this way — it goes beyond just thinking, we are actively working to bring our P4 into the U.S. as well.
Andre Condra
analystI'll keep it to a single question. Let's stay on U.S. IQOS. As we're aware, the FDA's proposed standards for a U.S. menthol ban permit — or possibly will permit — certain exemptions. And given that your IQOS carries the MRTP designation, which is fairly distinctive compared with every one of its competitors, did you take that into account when you laid out your target of, as I recall, 10% market share by 2030, unless I'm wrong?
Jacek Olczak
executiveYes. I believe those are my words you're citing. Jacek speaking. Yes, I continue to hold the view that IQOS by 2030, given how it performs across the many other international markets, the 10% isn't out of — out of — reach; it can be a realistic ambitious — ambition or realistic dream. To be completely candid, though, as we examined this, we haven't attempted to factor in the possibility of menthol bans applying to certain other products. But you correctly point out that IQOS today is — 2 variants of IQOS authorized with the menthol flavor. Whether this becomes an accelerating factor or not, only the future will reveal. Yet I still believe that IQOS, in the current environment, thanks to its strength and the satisfaction it delivers to smokers, et cetera, holds that big potential from the base.
Jared Dinges
analystA few things from me, if you don't mind. To start, with the increase in CapEx you're anticipating for this year, I just wanted to ask — what frame should we use when considering CapEx levels past '23? Given the ZYN international expansion plans, is next year sort of a one-time situation?
Emmanuel Babeau
executiveLook, I think you should of course count on us to support the growth. As our volume expands, we need more capacity. So CapEx will be a reflection of that. There is definitely, with regard to ILUMA, a point at which we're adding capacity for ILUMA, and that is showing up as a meaningful investment. So you can see that in the 1.3. I would say we will certainly be investing on a regular basis in capacity for the Swedish Match business as a whole. So at this stage, I'm not in a position to say. I'm not providing guidance on '24. I certainly believe there is this transitional period during which we are building ILUMA capacity, and then, naturally, that will be supporting ILUMA's growth, and as you know, we are very ambitious when it comes to growing the overall product. So investments will come along with that. But naturally, they aren't of the same magnitude as what we've been doing to build IQOS capacity, with lower volume and a smaller base, so the long-term impact isn't the same anyway.
Jared Dinges
analystUnderstood. That's very clear. And regarding the second item, perhaps just concerning the healthcare and wellness segment, 2023 is going to be yet another year of investment. I'm aware you folks have discussed that likely being a multiyear investment cycle. However, I'm not sure whether you might offer any signal on when you believe that business could potentially begin contributing to growth? And perhaps as well, could you discuss your learnings thus far in those businesses you've acquired?
Jacek Olczak
executiveYes. Okay, so, first off, we've been very open about this from the start. To bring a few of those programs or products we're planning to the market, I've got to put the money in. We're also talking about how we'd rather have a really strong investment in the medical side — in medical cannabinoids, and so on. Each of these programs has solid, well-defined milestones for developing those products, which covers the clinical trials and meeting all the different regulatory requirements. That's roughly the shape of it. In the past, we set a bold goal of hitting $1 billion in revenue by 2025. There's a product pipeline in place, sure. What I find more compelling, though, is what happens with that business beyond 2025, because that's an investment with a longer horizon. Of course, when we put capital to work, we start by funding the things that are closest to us in the near and medium term. Obviously that includes heat-not-burns, plus IQOS and ILUMA rollouts into the U.S., and I won't list every opportunity one by one — but we also keep in mind that these businesses, along with Wellness and Healthcare, give us some really appealing openings further out. We've made really good use of our strengths—pairing our know-how in science and life sciences with our commercial side and so on. That's the way I see it. I figure that when we get together this September for Investors Day, we'll begin laying out a far more extended view from management's side regarding where PMI is headed—not merely across the coming year or two, but looking much further out. That's when I expect we'll get into greater specifics. Also, on a related note, I believe we can give a clearer response to your initial question for Emmanuel regarding CapEx. Since we're laying out a decade-long outlook for Philip Morris, we'll need to address that piece of the capital allocation picture too.
James Bushnell
executiveThanks. As we wrap up today's call, a quick reminder that our presentation at the CAGNY conference is set for February 22. And, as noted earlier, we intend to hold an Investor Day in September over in Switzerland. We'd love for you to take part in these events, whether you attend in person or virtually. That brings today's call to a close. Thanks once more for being with us. Should any follow-up questions come up, please reach out to the Investor Relations team.
Emmanuel Babeau
executiveThank you. Talk to you soon.
Jacek Olczak
executiveThank you.
Operator
operatorThat concludes today's teleconference. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.